AI Article Synopsis

  • * Despite a good prognosis, cSCC leads to many deaths because of its high occurrence, highlighting the importance of ongoing research and treatment recommendations.
  • * A group of experts from various European dermatological and oncology organizations has come together to update guidelines on cSCC, focusing on various aspects such as classification, diagnosis, risk factors, and prevention for both immunocompetent and immunosuppressed individuals.

Article Abstract

Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly has very good prognosis after treatment, with 5-year cure rates greater than 90%. Despite the overall favourable prognosis and the proportionally rare deaths, cSCC is associated with a high total number of deaths due to its high incidence. A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV) and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update recommendations on cSCC, based on current literature and expert consensus. Part 1 of the guidelines addresses the updates on classification, epidemiology, diagnosis, risk stratification, staging and prevention in immunocompetent as well as immunosuppressed patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2023.113251DOI Listing

Publication Analysis

Top Keywords

invasive cutaneous
8
cutaneous squamous
8
squamous cell
8
cell carcinoma
8
european
7
european consensus-based
4
consensus-based interdisciplinary
4
interdisciplinary guideline
4
guideline invasive
4
carcinoma diagnostics
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!